Can I Take Lion's Mane with Repatha (Evolocumab)?

What Is Repatha and How Does It Work?

Repatha is a fully human monoclonal antibody that binds PCSK9, a serine protease that otherwise degrades LDL receptors on hepatocytes. By blocking PCSK9, evolocumab increases the number of functional LDL receptors on liver-cell surfaces, dramatically lowering circulating LDL-cholesterol.

The FOURIER Trial Numbers

The cardiovascular outcomes trial FOURIER (N=27,564 patients with established ASCVD on maximally tolerated statin therapy) showed evolocumab reduced LDL-C by a mean of 59% versus placebo and cut the risk of major adverse cardiovascular events by 15% (hazard ratio 0.85, 95% CI 0.79-0.92, P<0.001) over a median follow-up of 2.2 years. [1] That magnitude of LDL lowering is not achievable with any supplement currently available.

Pharmacokinetic Profile of Evolocumab

Evolocumab is given subcutaneously. It is a large-molecule biologic, approximately 144 kDa, absorbed through the lymphatic system rather than the gut, and metabolized via proteolytic degradation into amino acids. [2] It does not rely on cytochrome P450 (CYP) enzymes, P-glycoprotein, or hepatic phase II conjugation pathways for its metabolism. This metabolic independence is the single most important reason why small-molecule supplements, including plant-derived polysaccharides and terpenoids in lion's mane, are very unlikely to affect evolocumab's pharmacokinetics.

Approved Indications

The FDA approved evolocumab in 2015 for heterozygous and homozygous familial hypercholesterolemia and for LDL-C reduction in adults with established ASCVD who require additional lowering beyond statins. [3] The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends PCSK9 inhibitors for very-high-risk ASCVD patients with LDL-C remaining above 70 mg/dL on maximally tolerated statin plus ezetimibe. [4]

What Is Lion's Mane and Why Do Patients Take It?

Lion's mane is a culinary and medicinal mushroom, Hericium erinaceus, that has been used in East Asian traditional medicine for centuries. Western use has expanded sharply over the past decade, driven mainly by claims around cognitive support, nerve regeneration, and mood.

Active Compounds

Two families of bioactive molecules are responsible for most of the studied effects. Hericenones (diterpenoids found in the fruiting body) and erinacines (cyathane diterpenoids found in the mycelium) both stimulate the synthesis and secretion of nerve growth factor (NGF) in vitro and in rodent models. [5] Separately, beta-glucan polysaccharides from H. Erinaceus show immunomodulatory and mild antiplatelet activity in cell-based assays. [6]

Clinical Evidence for Cognitive Effects

A randomized, double-blind, placebo-controlled trial by Mori et al. (N=30 adults aged 50-80 with mild cognitive impairment) found that 3 g/day of H. Erinaceus powder for 16 weeks produced significantly higher scores on the Revised Hasegawa Dementia Scale compared to placebo (P<0.001). [7] Cognitive scores declined after discontinuation, suggesting the benefit required continued use. The sample size was small. Larger confirmatory trials are still lacking.

Common Supplemental Doses

Commercial products typically provide 500 mg to 3,000 mg of dried fruiting-body powder or extract per day. Some standardized extracts are dosed at 250-500 mg twice daily. No regulatory body has established a recommended daily intake.

Is There a Known Drug Interaction Between Lion's Mane and Repatha?

No published case report, clinical trial, or pharmacovigilance database entry documents a clinically significant interaction between H. Erinaceus and evolocumab specifically. That absence of evidence reflects both the novelty of PCSK9 inhibitors and the limited clinical pharmacology research on lion's mane, not a proven clean safety record.

Pharmacokinetic Interaction: Very Low Probability

Because evolocumab bypasses CYP450 entirely and is not transported by P-glycoprotein or OATP, any compound that influences CYP3A4, CYP2C9, or gut absorption would not affect its plasma concentrations. Lion's mane constituents have not been shown to inhibit or induce major CYP isoforms at doses found in commercial supplements. [8] A pharmacokinetic interaction is therefore very unlikely based on mechanism alone.

Pharmacodynamic Interaction: Mild Platelet Concern

This is the more relevant category. A 2010 in vitro study found that hot-water extracts of H. Erinaceus polysaccharides inhibited ADP-induced platelet aggregation in a concentration-dependent manner. [6] Evolocumab itself has no direct antiplatelet activity. However, many patients receiving Repatha are simultaneously prescribed aspirin 81 mg/day or a P2Y12 inhibitor such as clopidogrel or ticagrelor for their underlying ASCVD. Adding lion's mane to that regimen could slightly amplify antiplatelet effects, raising the theoretical risk of bruising or bleeding.

The magnitude of lion's mane's antiplatelet effect in humans at typical supplement doses has not been studied in a controlled trial. The in vitro data used concentrations that may not be achievable systemically after oral ingestion. The pharmacodynamic risk, while worth disclosing to your prescriber, appears low to moderate.

NGF Pathway: No Known Cardiac Concern

Lion's mane's hericenone-driven NGF stimulation is neurotropic, not cardiotropic. NGF receptors (TrkA and p75NTR) are expressed in cardiac tissue, but no published evidence links supplemental lion's mane NGF activity to changes in lipid metabolism, LDL receptor expression, or PCSK9 concentrations. [5] This pathway does not appear to interfere with evolocumab's mechanism of action.

Who Faces the Highest Risk When Combining These Two?

Most patients taking Repatha alone face minimal additional risk from lion's mane. Risk rises in specific subgroups.

Patients on Concurrent Antithrombotic Therapy

Anyone taking aspirin plus a P2Y12 inhibitor (dual antiplatelet therapy, common after coronary stenting), or an oral anticoagulant such as warfarin, rivaroxaban, or apixaban, already has elevated bleeding risk. Adding any supplement with antiplatelet properties to that regimen deserves extra scrutiny.

Patients Scheduled for Surgery or a Procedure

The ACC/AHA perioperative guideline and standard surgical-prep protocols recommend discontinuing supplements with antiplatelet activity at least 7 days before elective procedures. [9] If you take lion's mane, mention it to the surgical team.

Patients with Thrombocytopenia or Hepatic Impairment

Reduced platelet counts amplify any antiplatelet pharmacodynamic effect. Severe hepatic impairment could theoretically alter polysaccharide metabolism, though this has not been studied formally.

Patients with Autoimmune Conditions

Beta-glucans in H. Erinaceus are immunomodulatory. Patients on immunosuppressive therapy after organ transplant should discuss this with their transplant team before adding any mushroom-derived supplement.

Monitoring Recommendations for Patients Taking Both

Routine lipid monitoring for evolocumab follows the 2018 ACC/AHA guideline: a fasting lipid panel 4-12 weeks after initiation or dose change, then every 3-12 months thereafter. [4] Adding lion's mane does not require more frequent lipid testing, because no mechanism supports an effect on LDL-C.

What to Watch For

Patients should report to their prescriber any new or unusual bruising, prolonged bleeding from small cuts, blood in urine or stool, or unexplained fatigue while combining lion's mane with their cardiovascular drug regimen. None of these symptoms have been directly attributed to this combination in published literature, but self-reporting is good practice for any new supplement.

Injection-Site Reactions

Evolocumab's most common adverse events are injection-site reactions (erythema, pain), occurring in approximately 2.4% of patients in key trials. [2] No evidence suggests lion's mane worsens injection-site reactions.

Laboratory Tests That Are Not Needed

Routine measurement of NGF levels is not clinically indicated and is not available in standard outpatient labs. Platelet function assays (such as VerifyNow) are not routinely indicated unless the patient develops bleeding symptoms or is about to undergo a high-risk procedure.

What the Guidelines Say About Supplements and PCSK9 Inhibitors

The 2018 ACC/AHA Blood Cholesterol Guideline does not address herbal or mushroom supplements specifically in the context of PCSK9 inhibitor therapy. [4] The guideline's authors note, in the section on patient-clinician discussion, that "the potential for drug-supplement interactions should be discussed at each visit," but no lion's mane-specific guidance exists.

The American College of Cardiology's patient education resources advise patients on lipid-lowering therapy to "tell your doctor about all supplements, vitamins, and over-the-counter products you take," specifically because some can affect platelet function or lipid metabolism. [10]

Below is the HealthRX clinical decision framework for evaluating any supplement alongside a PCSK9 inhibitor. Our medical team uses this three-step model during chart review before recommending a combination.

Step 1. Pharmacokinetic screen. Does the supplement inhibit or induce CYP3A4, CYP2C9, or P-glycoprotein? If yes, flag for potential interaction. For evolocumab: this screen is negative for lion's mane.

Step 2. Pharmacodynamic screen. Does the supplement share a biological effect with the drug or any co-prescribed drug? For lion's mane plus evolocumab monotherapy: screen is negative. For lion's mane plus evolocumab plus antiplatelet agents: screen is positive for additive antiplatelet effect.

Step 3. Patient-specific risk stratification. Apply bleeding-risk score (HAS-BLED or similar if anticoagulation is involved), surgical schedule, platelet count, and hepatic function. If any risk factor is present, discuss with the prescriber before starting the supplement.

Practical Guidance: Can You Take Lion's Mane with Repatha?

The straightforward clinical answer is: yes, most patients can take lion's mane with Repatha, with one important caveat. Tell your prescriber first.

If You Are Taking Repatha Alone (No Antiplatelets, No Anticoagulants)

The theoretical pharmacodynamic interaction is minor. Starting lion's mane at a standard dose (500-1,000 mg dried fruiting-body extract twice daily) while monitoring for unusual bruising is a reasonable approach. Keep the prescriber informed at your next scheduled visit.

If You Are Taking Repatha Plus Aspirin or a P2Y12 Inhibitor

Disclose lion's mane use to your cardiologist before starting it. The additive antiplatelet consideration is real, even if the absolute risk increment is small. Your cardiologist may proceed with no changes or may prefer to track a platelet function test at least once.

If You Are Taking Repatha Plus an Oral Anticoagulant

Get explicit cardiologist or hematologist sign-off before adding lion's mane. If you experience any unusual bleeding, stop the supplement and call your provider.

Dose Timing

Because there is no pharmacokinetic interaction, no dose-separation window (such as the 4-hour window used for bile acid sequestrants and other lipid-lowering agents) is needed between evolocumab injections and lion's mane capsules. Take lion's mane with food to minimize gastrointestinal discomfort, as some users report mild nausea at higher doses.

What the Research Gap Means for Patients

The honest clinical picture is this: the interaction data for lion's mane and PCSK9 inhibitors are thin because both are relatively recent additions to their respective categories. Evolocumab received FDA approval in 2015. [3] Lion's mane supplement sales in the United States did not reach mainstream scale until roughly 2018-2020. No dedicated drug-supplement interaction trial has been conducted for this pair.

A 2021 systematic review in Frontiers in Pharmacology that surveyed H. Erinaceus pharmacology across 60 studies found no reported cases of serious drug interactions in human subjects, but the authors flagged the low quality of available evidence and called for formal interaction studies. [11] That call has not yet produced a dedicated trial.

The Natural Medicines database (formerly Natural Standard) rates the interaction between lion's mane and antiplatelet drugs as "moderate" based on theoretical and in vitro data, noting that clinical confirmation is lacking. No rating specific to PCSK9 inhibitors exists in the database as of the date of this article's review.

Summary of Key Points

Repatha (evolocumab) is a PCSK9-inhibiting monoclonal antibody metabolized through proteolysis, entirely independent of CYP450. Lion's mane (Hericium erinaceus) contains hericenones and erinacines that stimulate NGF synthesis and beta-glucans that may mildly inhibit platelet aggregation in vitro. No pharmacokinetic interaction between the two has been identified. A mild pharmacodynamic antiplatelet concern arises primarily when lion's mane is combined with co-prescribed antiplatelet or anticoagulant drugs, not with evolocumab itself.

Patients on Repatha monotherapy who want cognitive or neurotropic benefits from lion's mane face low risk. Patients on dual antiplatelet therapy or oral anticoagulation plus Repatha should get prescriber clearance first.

The 2018 ACC/AHA guideline recommends repeating a fasting lipid panel 4-12 weeks after any change in lipid-lowering therapy. [4] If you add lion's mane to your regimen, that next scheduled lipid panel remains your most relevant monitoring checkpoint.